BiomX Ltd.

www.biomx.com

Formerly MBcure

High-Tech Company
Public Company

(NYSE: PHGE)

Graduated from: FutuRx

TECH VERTICALS

Artificial Intelligence, Biotechnology, Computational Biology, Deep Tech, Healthtech, Life Sciences, MedTech, Pharmaceuticals, Synthetic Biology, Therapeutics

General Data

Sector	Biomed
Company Stage:	R&D
Established	2015
Number of Employees	65
Employees in Israel	50
Reg. Number:	abCDe

DESCRIPTION

BiomX is a clinical-stage company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

TECHNOLOGY

BiomX is developing synbio phage therapies to eradicate harmful bacteria in chronic diseases.

Products and Phases

Product	Phase
Cystic Fibrosis (CF) - BX004	Phase II
BX004 is being developed for the treatment of chronic respiratory infections caused by Pseudomonas aeruginosa, a main contributor to morbidity and mortality in patients with Cystic Fibrosis.
Diabetic Foot Osteomyelitis - BX211	Phase II
BX211 is being developed for the treatment of diabetic foot osteomyelitis caused by Staphylococcus aureus, a main contributor to lower extremity amputations in diabetic patients.
Diabetic Foot Infections - BX011	Phase II
BX011 is being developed for the treatment of diabetic foot infections caused by Staphylococcus aureus, a main contributor to lower extremity amputations in diabetic patients.
Non-CF Bronchiectasis (NCFB) BX004
Following positive Phase 1b/2a results of BX004 in Cystic Fibrosis patients, BiomX is conducting preclinical studies to evaluate its potential use in Non-CF Bronchiectasis (‘NCFB’) patients with similar chronic respiratory infections. Currently in Pre-Clinical Studies.

	TARGET MARKETS
	Therapeutics Companies, Physicians, Dermatologists, Pulmonologists.

	BUSINESS MODEL
	B2C

AFFILIATION

Account ID	Affiliation Type	Name	Parent Name	Status
006A4146-61C8-E511-BD22-80C16E7D3630		BiomX Ltd.
	Subsidiary	X Security & Defense	BiomX Ltd.

REMARKS

Date	Remark
17/12/2025	BiomX has filed an urgent petition for insolvency proceedings after its clinical program collapsed, burdened by more than NIS 11m in debt and rapidly dwindling cash reserves. The company is now seeking a court-appointed trustee to assess potential buyers for its remaining assets, with the Cystic Fibrosis Foundation already expressing preliminary interest in a possible acquisition.

CONTACT INFO

Expand / Collapse All

Main Address: Ness Ziona, Israel

Address	22 Einstein St., 5th Floor
City	Ness Ziona
Country	Israel
Zip	7414003

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Gaithersburg, United States

Address	708 Quince Orchard Rd., Suite 205
City	Gaithersburg
State/Province	MD
Country	United States
Zip	20878

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Mr. Jonathan Solomon	CEO	Medtronic Israel (Responsible for Defining Future Products)
Ms. Marina Wolfson	CFO	BioView (VP, Finance)
Ms. Inbal Benjamini-Elran	Chief Human Resources Officer
Prof. Eran Elinav	Scientific Co-Founder
Prof. Timothy Lu	Scientific Co-Founder
Dr. Carl Merril	Scientific Co-Founder
Prof. Rotem Sorek	Scientific Co-Founder
Mr. Assaf Oron	CBO	Evogene (EVP, Corporate Development)

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Chairman	President & Founder, Greig Biotechnology Global Consulting
abC Defghij	Board Member	Former Chief Medical Officer & SVP, Joslin Diabetes Center, Boston
abC Defghij	Board Member	Chairman, Deerfield Institute
abC Defghij	Board Member	Founder & Managing Partner, Velocity Biofund
abC Defghij	Board Member	Director, Center on Medical Product, Safety and Stewardship, Georgetown University
abC Defghij	Board Member	CEO, BiomX
abC Defghij	Board Member	Chief Financial Officer, Melinta Therapeutics
abC Defghij	Board Member	Former Special Advisor, Ascendis Pharma

Mergers & Acquisitions

Round

Date

Stage

Amount

Valuation

Reverse Merger

Oct. 29, 2019

R&D

abCDe

Public Offerings

Deal Date	Type of Offering	Exchange	Amount Raise	Valuation	Remarks
Feb. 26, 2025	Third Public Offering	NYSE	abCDe	abCDe	Registered Direct Offering ; Additional $8.6m were raised in a concurrent private placement and exercise of warrants.
Jul. 26, 2021	Second Public Offering		abCDe	abCDe	Registered Direct Offering
Feb. 06, 2020	Dual Listing	TASE	abCDe	abCDe	10/2022: Delisted from TASE

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

PIPE

Feb. 26, 2025

Revenue Growth

abCDe

$2.1m in a concurrent private placement; $6.5m in exercise of warrants issued on March 15, 2024; Additional $3.4m were raised in a registered direct offering.

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Hedge Fund	abCDe
abC Defghij	Endowment & Foundation	abCDe
abC Defghij	Investment Company	abCDe	Led the round
abC Defghij	Other	abCDe

PIPE

Mar. 18, 2024

Revenue Growth

abCDe

PIPE

Feb. 22, 2023

Revenue Growth

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Endowment & Foundation	abCDe
abC Defghij	Other	abCDe

PIPE

Jan. 04, 2022

R&D

abCDe

A Therapeutics Development Award as an equity investment.

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Endowment & Foundation	abCDe	the CF Foundation invested $3 million as initial equity investment. Upon completion of a certain milestone, BiomX would have the right to receive a second tranche of $2 million, also as an equity investment.

Second Round

Feb. 20, 2019

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe	Round co-leader
abC Defghij	Corporate VC	abCDe	Round co-leader
abC Defghij	Corporate VC	abCDe
abC Defghij	Private Equity Fund	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	High-Tech Company	abCDe
abC Defghij	High-Tech Company	abCDe

First Round - Extended

Dec. 19, 2017

R&D

abCDe

First Round

May. 15, 2017

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe	Round co-leader
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Corporate VC	abCDe	Round co-leader
abC Defghij	Corporate VC	abCDe	Round co-leader
abC Defghij	Private Investor	abCDe
abC Defghij	Other	abCDe

Seed

Sep. 01, 2015

Seed

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe	Led the round
abC Defghij	Technology Transfer Company	abCDe
abC Defghij	Government Agency	abCDe	R&D Grant
abC Defghij	Incubator	abCDe

	R&D Grants

Expand / Collapse All

Round

Date

Stage

Amount

Remarks

R&D Grant

May. 01, 2024

Revenue Growth

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

R&D Grant

Mar. 01, 2023

Revenue Growth

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

R&D Grant

Mar. 01, 2022

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

	Acquisitions made by BiomX

Acquired Company	Sector	Date	Amount	Remarks
abC Defghij	Biomed...	Mar. 18, 2024	abCDe
abC Defghij	Medica...	Dec. 19, 2017	abCDe

Last Updated:	abCDe
IVC Number:	abCDe